David A. Reardon

Active 1997–2025

Also published as
David A Reardon
269
Papers
56,227
Citations
121
h-index
257
i10-index

Citations

Citations per year for David A. Reardon1990: 1 citations1994: 1 citations1998: 2 citations1999: 10 citations2000: 7 citations2001: 15 citations2002: 19 citations2003: 30 citations2004: 49 citations2005: 63 citations2006: 171 citations2007: 169 citations2008: 220 citations2009: 327 citations2010: 362 citations2011: 420 citations2012: 413 citations2013: 349 citations2014: 466 citations2015: 479 citations2016: 381 citations2017: 660 citations2018: 505 citations2019: 1,750 citations2020: 2,424 citations2021: 2,642 citations2022: 2,415 citations2023: 2,124 citations2024: 3,298 citations2025: 1,664 citations2026: 59 citations1991–1993: no citations, so these years are not shown1995–1997: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 6,397 citing papers, 29.5% of this breakdownChina: 2,792 citing papers, 12.9% of this breakdownGermany: 1,513 citing papers, 7% of this breakdownUnited Kingdom: 1,001 citing papers, 4.6% of this breakdownItaly: 939 citing papers, 4.3% of this breakdownFrance: 838 citing papers, 3.9% of this breakdownCanada: 737 citing papers, 3.4% of this breakdownNetherlands: 698 citing papers, 3.2% of this breakdownSwitzerland: 664 citing papers, 3.1% of this breakdownAustralia: 479 citing papers, 2.2% of this breakdownJapan: 460 citing papers, 2.1% of this breakdownSpain: 451 citing papers, 2.1% of this breakdown
0%29.5%Other 21.7%

Fields

  • Medicine63.3%
  • Biochemistry, Genetics and Molecular Biology20.6%
  • Immunology and Microbiology8.1%
  • Neuroscience2.5%
  • Engineering2.2%
  • Materials Science1.3%
  • Other2%

Topics

  • Glioma Diagnosis and Treatment14.8%
  • Cancer Immunotherapy and Biomarkers4.8%
  • Brain Metastases and Treatment4.3%
  • Immunotherapy and Immune Responses3.4%
  • CAR-T cell therapy research2.6%
  • Cancer, Hypoxia, and Metabolism2.5%
  • Other67.6%

Coauthors

All papers

Open in search
  1. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2020 cited by 1,457

  2. IDH1andIDH2Mutations in Gliomas

    Authors: , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2009 cited by 5,928

  3. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martin Taphoorn, Joerg-Christian Tonn, Jonathan Tsang, Roel G.W. Verhaak, Andreas von Deimling, Wolfgang Wick, Gelareh Zadeh, David A. Reardon, Kenneth Aldape, Martin J. van den Bent - Neuro-Oncology 2020 cited by 1,137

  4. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Heather Daley, Patrick Y. Wen, E. Antonio Chiocca, Maegan Harden, Niall J. Lennon, Stacey Gabriel, Gad Getz, Eric S. Lander, Aviv Regev, Jerome Ritz, Donna Neuberg, Scott J. Rodig, Keith L. Ligon, Mario L. Suvà, Kai W. Wucherpfennig, Nir Hacohen, Edward F. Fritsch, Kenneth J. Livak, Patrick A. Ott, Catherine J. Wu, David A. Reardon - Nature 2018 cited by 1,464

  5. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2019 cited by 1,387

  6. Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2010 cited by 3,829

  7. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Neuro-Oncology 2022 cited by 501

  8. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Neuro-Oncology 2022 cited by 485

  9. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 462

  10. Clinical trial links oncolytic immunoactivation to survival in glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Scott J. Rodig, Patrick Y. Wen, Eudocia Q. Lee, Lakshmi Nayak, Ugonma Chukwueke, L. Nicolas Gonzalez Castro, Sydney Dumont, Tracy T. Batchelor, Kara A. Kittelberger, Ekaterina Tikhonova, Natalia Miheecheva, D Tabakov, Nara Shin, Alisa M. Gorbacheva, Artemy Shumskiy, Felix Frenkel, Estuardo Aguilar-Córdova, Laura K. Aguilar, David Krisky, James Wechuck, Andrea G. Manzanera, Christopher Matheny, Paul P. Tak, Francesca Barone, Daniel Kovarsky, Itay Tirosh, Mario L. Suvà, Kai W. Wucherpfennig, Keith L. Ligon, David A. Reardon, E. Antonio Chiocca - Nature 2023 cited by 256

  11. Mechanisms and therapeutic implications of hypermutation in gliomas

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Maïté Verreault, Marine Giry, Erell Guillerm, Samy Ammari, Frédéric Beuvon, Karima Mokhtari, Agustí Alentorn, Caroline Dehais, Caroline Houillier, Florence Laigle–Donadey, Dimitri Psimaras, Eudocia Q. Lee, Lakshmi Nayak, J Ricardo McFaline-Figueroa, Alexandre Carpentier, Philippe Cornu, Laurent Capelle, Bertrand Mathon, Jill S. Barnholtz‐Sloan, Arnab Chakravarti, Wenya Linda Bi, E. Antonio Chiocca, Katie Fehnel, Sanda Alexandrescu, N. Susan, Daphne A. Haas‐Kogan, Tracy T. Batchelor, Garrett M. Frampton, Brian M. Alexander, Raymond Y. Huang, Azra H. Ligon, Florence Coulet, Jean‐Yves Delattre, Khê Hoang‐Xuan, David M. Meredith, Sandro Santagata, Alex Duval, Marc Sanson, Andrew D. Cherniack, Patrick Y. Wen, David A. Reardon, Aurélien Marabelle, Peter J. Park, Ahmed Idbaïh, Rameen Beroukhim, Pratiti Bandopadhayay, Franck Bielle, Keith L. Ligon - Nature 2020 cited by 720

  12. Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Neuroscience 2019 cited by 526

  13. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Burt Nabors, David A. Reardon, Martin J. van den Bent, Christine Hicking, Andriy Markivskyy, Martin Picard, Michael Weller - The Lancet Oncology 2014 cited by 1,019

  14. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 1,321

  15. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew P. Frosch, David N. Louis, Gordon J. Freeman, Keith L. Ligon, Alexander Marson, E. Antonio Chiocca, David A. Reardon, Aviv Regev, Mario L. Suvà, Kai W. Wucherpfennig - Cell 2021 cited by 412

  16. Molecular targeted therapy of glioblastoma

    Authors: , , , , , , , - Cancer Treatment Reviews 2019 cited by 724

  17. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 322

  18. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Patrick Y. Wen - Neuro-Oncology 2022 cited by 237

  19. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 257

  20. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alison Y. Zhang, Hans Prenen, Jean‐Charles Goeminne, Jean‐Pascal Machiels, Sylvie Rottey, Marcelo Corassa, Graziela Zibetti Dal Molin, Katsuki Arima Tiscoski, Denis L. Jardim, Milena Perez Mak, Wei Fu, Herui Yao, Jing Huang, Haiping Jiang, Jing Huang, Baoshi Chen, Dong Yan, Yu Yang, Yohann Loriot, Christophe Le Tourneau, Nicolas Penel, Sébastien Salas, Jean‐Yves Blay, Pierre-Emmanuel Brachet, Xavier Durando, Sheik Emambux, Alain Ravaud, Gunnar Folprecht, Dirk Arnold, Martin Schüler, Marit Ahrens, Alexander Golf, Georg Martin Haag, Florian Lordick, Alexander Desuki, Marina Elena Cazzaniga, Fortunato Ciardiello, Michèle Milella, Takafumi Koyama, Yoshiki Hirooka, Wataru Okamoto, Kenjiro Aogi, Yasutoshi Kuboki, Jung-Yun Lee, Sung‐Bae Kim, Myung‐Ju Ahn, Jong Hee Chang, Yongman Kim, Do‐Hyun Nam, Jaesung Park, Iwona Ługowska, Luis Paz‐Ares, Víctor Moreno, Andrés Cervantes, Mariona Calvo, Alejandro Falcón, Antonio González, Josep Tabernero, A. Martinez Bueno, Javier García-Corbacho, Federico Longo, Chia‐Jui Yen, Jen‐Shi Chen, Ming‐Feng Hou, Yee Chao, Kun‐Ming Rau, Tai‐Jan Chiu, Yin‐Hsun Feng, Chih‐Hung Hsu, Wen‐Tsung Huang and 33 more - The Lancet Oncology 2023 cited by 200

  21. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 cited by 763

  22. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 159

  23. Glial and myeloid heterogeneity in the brain tumour microenvironment

    Authors: , , , , , - Nature reviews. Cancer 2021 cited by 210

  24. Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response

    Authors: , , , , , , , , , , , , , , , - Immunity 2022 cited by 138